Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Edor Kabashi wins the International Medicine PG Award for Amyotrophic Lateral Sclerosis (ALS) research

Published on: 26/10/2016 Reading time: 1 min
Edor Kabashi

The Paulo Gontijo Institute awarded the International Medicine PG Award to Edor Kabashi, team leader at the Brain and Spine Institute – Institut du Cerveau, for his research on the development of new models and new therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

Edor Kabashi joined the Brain and Spine Institute - Institut du Cerveau - ICM in 2011 as the “Treatment of Amyotrophic lateral sclerosis: from genetics to zebrafish” team leader. He obtained his PhD in 2008 at McGill University and did postdoctoral work at Centre of Excellence in Neuromics at University of Montreal. He received many awards, including the Brain Star Award of CIHR Institute of Neuroscience in 2009 and 2011, and the Young investigator award from European Network for the Cure of ALS in 2015.

The International Medicine PG Award is an initiative of the Paulo Gontijo Institute to foster the research of young researchers around the world to promote the cure of ALS.

Selected from 15 studies, Kabashi’s studies have provided a breakthrough in developing new models and therapeutic avenues for Amyotrophic Lateral Sclerosis (ALS).

 

“My team works to better understand how a variety of genetic mutations can cause motor neuron degeneration in ALS. We take advantage of a simple vertebrate model, zebrafish where one or several genes can be manipulated. Using this paradigm, we have described that several major ALS genes interact together and function in common pathways and we are currently identifying drugs which could affect these molecular targets”, says Edor Kabashi.

 

The International Medicine PG Award is recognized by the international scientific community. Its partners the International Alliance of ALS, Motor Neuron Disease Association (MNDA) and the European Community for research for the cure of ALS (ENCALS). The study results will be presented at opening ceremony of the 26th International Symposium on ALS / MND (motor neuron disease) to be held in Dublin (Ireland) in December.

Our news on the subject

Une personne écrit sur un tableau
Looking back at the “Brain to Market” Summer School 2024 dedicated to motor neurone disease
From September 9 to 13, the Open Brain School, the education center at Paris Brain Institute, organized the 10th edition of its flagship training program in neuroscience and entrepreneurship—dedicated to fostering innovation. This event brought the...
10.07.2024 Teaching & training
Interneurones. Crédit : UCLA Broad Stem Cell Research Center.
Stimulating specific neurons in the striatum stops compulsive behaviour
What if we could resist compulsions? These irrational behaviours, particularly common in obsessive-compulsive disorder (OCD), are hard to suppress. At Paris Brain Institute, Éric Burguière's team shows that we can anticipate them and block them...
09.10.2024 Research, science & health
Les nerfs moteurs présents dans la moelle épinière se projettent vers la périphérie, où ils entrent en contact avec les muscles, formant des connexions appelées jonctions neuromusculaires. Crédit : James N. Sleigh.
Ultrasound show unexpected effects on motor neuron disease
Over the past fifteen years, neurosurgeons have been perfecting a fascinating technique: using ultrasound to temporarily open the blood-brain barrier to facilitate the action of therapeutic molecules in the central nervous system. At Paris Brain...
09.05.2024 Research, science & health
Un neurone
Rett syndrome: a new gene therapy on the way
Gene therapy could be our best chance of treating Rett syndrome, a neurological disorder that causes severe intellectual and motor impairments. At Paris Brain Institute, Françoise Piguet and her colleagues have looked closely at brain cholesterol...
07.16.2024 Research, science & health
Lésions d’un patient à l’inclusion dans le protocole (M0) disparues après 2 ans de traitement à la Leriglitazone (M24)
The dual effect of leriglitazone in X-linked Adrenoleukodystrophy (X-ALD)
In 2023, the team led by Professor Fanny Mochel (AP-HP, Sorbonne University), a Paris brain Institute researcher, showed that daily dose of leriglitazone slow down the progression of myelopathy in patients with X-linked adrenoleukodystrophy, and...
06.28.2024 Research, science & health
Une tête de statue de l'île de Pâques sur laquelle sont posées des éléctrodes
A multimodal approach to better predict recovery in patients with disorders of consciousness
When a patient is admitted to intensive care due to a disorder of consciousness—such as a coma—establishing their neurological prognosis is a crucial yet challenging task. To reduce the uncertainty that precedes the medical decision, a group of...
05.30.2024 Research, science & health
See all our news